Form 4: Sarepta Therapeutics Director Hans Wigzell Exercises Options and Sells Shares

Director Hans Wigzell of Sarepta Therapeutics exercised stock options and sold shares on December 12, 2024.

Summary

• Hans Wigzell, a director at Sarepta Therapeutics, exercised 10,500 stock options at a price of $13.71 per share on December 12, 2024.
• Following the exercise of options, Mr. Wigzell sold 10,500 shares of common stock at a weighted average price of $124.84 per share on the same day.
• The sale of shares occurred in multiple transactions with prices ranging from $124.80 to $124.92.
• After these transactions, Mr. Wigzell directly owns 22,840 shares of Sarepta Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document is a neutral report of insider trading activity, with no inherent positive or negative sentiment.

Industry Context

This is a routine filing related to insider trading activity, which is common for directors and officers of publicly traded companies. It provides transparency into the transactions of company insiders.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, and this filing is consistent with those requirements.
• The transactions are typical for directors who receive stock options as part of their compensation.

Stakeholder Impact

• The transaction has a minor impact on shareholders as it represents a small portion of the total outstanding shares.
• The sale of shares by a director could be perceived as a negative signal by some investors, but it is a common practice.

Key Dates

Keywords

Sarepta Therapeutics, insider trading, stock options, share sale, Form 4, Hans Wigzell, director